| Literature DB >> 34203580 |
Chun-Ya Kang1, Eugene Yu-Chuan Kang2,3, Chi-Chun Lai2,3,4, Wei-Che Lo5, Kun-Jen Chen2,3, Wei-Chi Wu2,3, Laura Liu2,3, Yih-Shiou Hwang2,3, Fu-Sung Lo2,6, Yhu-Chering Huang2,7.
Abstract
Nasal <span class="Chemical">methicillin-resistant <span class="Species">Staphylococcus aureus (MRSA) colonies are an essential reservoir of infection, especially for patients with diabetes. However, data on MRSA colonization in patients with type 1 diabetes are limited. We investigated the epidemiology of MRSA colonization in patients with type 1 diabetes. This prospective cross-sectional study was conducted in a medical center (Chang Gung Memorial Hospital) in Taiwan from 1 July to 31 December 2020. Nasal sampling and MRSA detection were performed. The molecular characteristics of MRSA isolates were tested, and factors associated with MRSA colonization were analyzed. We included 245 patients with type 1 diabetes; nasal MRSA colonization was identified in 13 (5.3%) patients. All isolates belonged to community-associated MRSA genetic strains; the most frequent strain was clonal complex 45 (53.8%), followed by ST59 (30.8%) (a local community strain). MRSA colonization was positively associated with age ≤ 10 years, body mass index < 18 kg/m2, and diabetes duration < 10 years; moreover, it was negatively associated with serum low-density lipoprotein cholesterol ≥ 100 mg/dL. No independent factor was reported. The nasal MRSA colonization rate in type 1 diabetes is approximately 5% in Taiwan. Most of these colonizing strains are community strains, namely clonal complex 45 and ST59.Entities:
Keywords: Staphylococcus aureus; epidemiology; methicillin-resistant; molecular; nasal colonization; type 1 diabetes
Year: 2021 PMID: 34203580 PMCID: PMC8232090 DOI: 10.3390/microorganisms9061296
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Demographics of patients with type 1 diabetes.
| Variates | Non-MRSA | MRSA | Total | |
|---|---|---|---|---|
| Male (no.) (%) | 112 (48.3) | 4 (30.8) | 116 (47.3) | 0.219 |
| Age (year) (mean ± SD) | 22.9 ± 6.5 | 14.4 ± 8.4 | 22.4 ± 6.8 | <0.001 |
| Age ≤ 10 years (%) | 13 (5.6) | 6 (46.2) | 19 (7.8) | 0.001 |
| Age > 10 years (%) | 219 (94.4) | 7 (53.8) | 226 (92.2) | |
| Diabetes duration (year) (mean ± SD) | 14.8 ± 6.0 | 8.4 ± 6.6 | 14.4 ± 6.2 | <0.001 |
| HbA1c (%) (mean ± SD) | 8.6 ± 2.0 | 8.4 ± 1.3 | 8.6 ± 2.0 | 0.714 |
| Body weight (kg) (mean ± SD) | 59.6 ± 14.1 | 42.5 ± 16.0 | 58.8 ± 14.6 | <0.001 |
| Height (cm) (mean ± SD) | 161.5 ± 12.7 | 141.7 ± 18.6 | 160.4 ± 13.7 | 0.002 |
| Body mass index (kg/m2) (mean ± SD) | 22.9 ± 0.3 | 19.6 ± 1.1 | 22.8 ± 5.6 | 0.037 |
| Hypertension (no.) (%) | 38 (16.4) | 1 (7.7) | 39 (15.9) | 0.699 |
| Serum creatinine (mg/dL) (mean ± SD) | 0.64 ± 0.16 | 0.45 ± 0.12 | 0.63 ± 0.16 | <0.001 |
| Serum HDL-C (mg/dL) (mean ± SD) | 62.6 ± 15.5 | 70.5 ± 16.6 | 63.0 ± 15.6 | 0.073 |
| Serum LDL-C (mg/dL) (mean ± SD) | 111.0 ± 34.1 | 95.5 ± 29.6 | 110.2 ± 34.0 | 0.110 |
| Serum total cholesterol (mg/dL) (mean ± SD) | 187.0 ± 42.0 | 181.2 ± 33.8 | 186.7 ± 41.6 | 0.625 |
| Serum triglyceride (mg/dL) (mean ± SD) | 81.4 ± 61.4 | 63.5 ± 41.3 | 80.5 ± 60.6 | 0.301 |
MRSA: methicillin-resistant Staphylococcus aureus; SD: standard deviation; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. * p value was obtained by chi-square test or Fisher’s exact test (when any expected count was less than 5) for categorial variates and by Student’s t-test for continuous variates.
Antibiotic susceptibility of nasal methicillin-resistant Staphylococcus aureus colonies.
| ID | CC | E | FA | LZD | P | SXT | TEC | VA | CIP | D |
|---|---|---|---|---|---|---|---|---|---|---|
| 01 | S | S | S | S | R | S | S | S | S | S |
| 02 | S | S | S | S | R | S | S | S | S | S |
| 03 | S | R | S | S | R | S | S | S | S | S |
| 04 | S | S | S | S | R | S | S | S | S | S |
| 05 | S | R | S | S | R | S | S | S | S | S |
| 06 | S | S | S | S | R | S | S | S | S | S |
| 07 | S | S | S | S | R | S | S | S | S | S |
| 08 | S | R | S | S | R | S | S | S | S | S |
| 09 | S | R | S | S | R | S | S | S | S | S |
| 10 | S | R | S | S | R | S | S | S | R | S |
| 11 | R | R | S | S | R | S | S | S | S | S |
| 12 | S | S | S | S | R | S | S | S | S | S |
| 13 | S | S | S | S | R | S | S | S | S | S |
CC: clindamycin; E: erythromycin; FA: fusidic acid; LZD: linezolid; P: penicillin; SXT: sulfamethoxazole–trimethoprim; TEC: teicoplanin; VA: vancomycin; CIP: ciprofloxacin; D: doxycycline; S: susceptible; R: resistant.
Figure 1Molecular characteristics of 13 methicillin-resistant Staphylococcus aureus isolates. Black color indicates positive. ST508 is a single-locus variant of ST45, and ST6587 is a single-locus variant of ST508. PFGE: pulsed-field gel electrophoresis; SCCmec: staphylococcal cassette chromosome mec; PVL: Panton–Valentine leukocidin; MLST, multilocus sequence type; Spa: staphylococcal protein A.
Univariate and multivariate analysis of clinical characteristics associated with methicillin-resistant Staphylococcus aureus colonization.
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| Odds Ratio | 95% CI | Odds Ratio | 95% CI | |||
| Male | 0.48 | 0.14–1.59 | 0.23 | |||
| Age | ||||||
| ≤10 years | 14.44 | 4.24–49.18 | <0.001 | 7.40 | 0.69–79.47 | 0.099 |
| >10 years | 0.07 | 0.02–0.24 | <0.001 | |||
| Body mass index | ||||||
| <18 kg/m2 | 7.10 | 2.21–22.79 | 0.001 | 0.63 | 0.06–6.36 | 0.698 |
| 19–24 kg/m2 | 0.43 | 0.14–1.37 | 0.153 | |||
| >24 kg/m2 | 0.44 | 0.10–2.03 | 0.292 | |||
| Diabetes duration | ||||||
| <10 years | 8.86 | 2.61–30.01 | <0.001 | 3.92 | 0.81–18.87 | 0.089 |
| ≥10 years | 0.12 | 0.03–0.39 | 0.001 | |||
| HbA1c | ||||||
| <7.0% | 0.74 | 0.16–3.43 | 0.696 | |||
| 7.0%–10.0% | 2.11 | 0.57–7.89 | 0.266 | |||
| >10% | 0.36 | 0.05–2.81 | 0.327 | |||
| Hypertension | 0.43 | 0.05–3.37 | 0.418 | |||
| Elevated LDL-C 1 | 0.27 | 0.08–0.89 | 0.032 | 0.29 | 0.08–1.10 | 0.068 |
| Elevated total cholesterol 2 | 0.93 | 0.30–2.94 | 0.907 | |||
| Elevated triglyceride 3 | 0.84 | 0.10–6.76 | 0.868 | |||
CI: confidence interval; HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol. 1 Defined as serum LDL-C level ≥ 100 mg/dL. 2 Defined as serum total cholesterol level ≥ 170 mg/dL in patients aged younger than 18 years and ≥ 200 mg/dL in patients aged older than 18 years. 3 Defined as serum triglyceride level ≥ 110 mg/dL in patients aged younger than 9 years and ≥ 150 mg/dL in patients aged older than 9 years.